Clinical Trial Update: A Study of Pirtobrutinib (LOXO-305) Versus Bendamustine Plus Rituximab (BR) in Untreated Patients With Chronic Lymphocytic Leukemia (CLL)/Small Lymphocytic Lymphoma (SLL) [Phase 3]

View source ↗

Summary

A Phase 3 clinical trial comparing pirtobrutinib to bendamustine plus rituximab in untreated chronic lymphocytic leukemia/small lymphocytic lymphoma is currentl…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Chronic Lymphocytic Leukemia
• Small Lymphocytic Lymphoma

Drugs mentioned

• Bendamustine (Bendamustine)
• Pirtobrutinib (pirtobrutinib)
• Rituximab (rituximab)

Snippet

Sponsor: Loxo Oncology, Inc. | Conditions: Chronic Lymphocytic Leukemia, Small Lymphocytic Lymphoma | Phase 3 | Status: ACTIVE_NOT_RECRUITING